<code id='7F459F2401'></code><style id='7F459F2401'></style>
    • <acronym id='7F459F2401'></acronym>
      <center id='7F459F2401'><center id='7F459F2401'><tfoot id='7F459F2401'></tfoot></center><abbr id='7F459F2401'><dir id='7F459F2401'><tfoot id='7F459F2401'></tfoot><noframes id='7F459F2401'>

    • <optgroup id='7F459F2401'><strike id='7F459F2401'><sup id='7F459F2401'></sup></strike><code id='7F459F2401'></code></optgroup>
        1. <b id='7F459F2401'><label id='7F459F2401'><select id='7F459F2401'><dt id='7F459F2401'><span id='7F459F2401'></span></dt></select></label></b><u id='7F459F2401'></u>
          <i id='7F459F2401'><strike id='7F459F2401'><tt id='7F459F2401'><pre id='7F459F2401'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:knowledge    Page View:19

          Has AI really solved biology? What can machines teach us about medicine? And what’s a digital twin?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. It’s our all-AI episode. First, STAT’s Casey Ross joins us to explain his reporting on how researchers and pharmaceutical firms are using the technology to find new drug targets, design therapies, and improve clinical trials. Then, we talk to Joel Dudley, a partner at the venture firm Innovation Endeavors, about how to discern promising ideas from wastes of time when it comes to AI in biotech.

          advertisement

          For more on what we cover, here’s the latest on AI in drug development; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          advertisement

          explore

          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more
          Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M
          Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

          CytokineticsCEORobertBlumspokelastweekatatalkduringSTAT’sBreakthroughSummitWestinSanFrancisco.SarahG

          read more
          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more

          As a primary care physician, here's how I hope to partner with AI

          AdobeIambothexcitedandterrifiedbytheentranceofartificialintelligenceintomyprimarycarepractice.AI’sen